FILING ANALYSIS · TUESDAY, OCTOBER 13
Nurix Therapeutics, Inc. NRIX — 8-K: Results of Operations and Financial Condition
positive
Nurix Therapeutics reported a strong quarter with significant corporate updates, including the dosing of the first patient in the registrational Phase 3 DAYBreak CLL-306 trial and the advancement of its wholly owned oncology portfolio, with a cash runway into the second half of 2029. The company also earned $27M from collaborations with Gilead, Pfizer, and Sanofi, and presented positive clinical d
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →